for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Sellas Enrolls First Patient In Early-Stage Trial Of Galinpepimut-S In Combination With Opdivo

Feb 11 (Reuters) - Sellas Life Sciences Group Inc:

* SELLAS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 1 TRIAL OF GALINPEPIMUT-S (GPS) IN COMBINATION WITH NIVOLUMAB (OPDIVO®) IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up